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http://dx.doi.org/10.1016/j.jsps.2014.04.002Cell culture is among the most widely used laboratory
approaches probably because of the diverse aspects it covers
and the relatively short period of time it requires. In pharmacol-
ogy and therapeutic researches, cell culture represents a largely
used basic approach. The aim of the modern pharmacology is
to ﬁrst identify active compounds from natural elements
(Larkins and Wynn, 2004; Ghanemi and Boubertakh, 2014;
Boubertakh et al., 2013; De Pasquale, 1984) that can constitute
a starting point to develop therapeutic drugs. Nowadays, the
drug development lies mainly on the identiﬁcation of com-
pounds that are thought to be active (Ghanemi, 2014a,b;
Winquist et al., 2014) based on their chemical structures
(Huryn and Wipf, 2014) or based on observation reported by
biologists or physiologists for example. Those compounds are
then further investigated.
The ﬁrst step in drug discovery is, in many cases, to test com-
pounds in cell culture to ﬁnd out how active they are in terms of
pharmacological actions. The challenges faced in this step are
diverse. Indeed, selecting the cell line is an important issue since
the compound activity may be speciﬁc. Deﬁning the optimum
conditions for both the cell culture media and the drug solvent,
in addition to the other reagents that are eventually used,
remains important since a variation of each of these factors
could affect the robustness of the cell-based assay by inﬂuenc-
ing the live cells (Ghanemi, 2014a), and therefore the assay’s
results. Another important element is the choice of the positive
control, which is in many cases a commonly used drug that is
well studied and well known for the activity we are about to
test. Importantly, the use of negative controls assures a better
interpretation of the results since it allows us to distinguish
the effects of the tested drugs from those due to other elements
such as the reagents or the cell culture medium ingredients.
For instance, many pharmacological discoveries related to
one of the most important pharmacological targets, G protein
coupled receptors (Ghanemi, 2013, 2014c, 2015; Ghanemi et al.,2013), have been made, thanks to cell cultures and the related
bio-molecularmethods.We expectmore advances due to the high
diversity of the existent cell strains and the similarities that exist
between the pathways within those cells and some human disease
mechanismswewant to elucidate in order to treat the underlying
causes instead of just managing the symptoms. Yet, an active
compound does necessary mean a future drug since toxicologi-
cal studies (Wang et al., 2014; Abdi, 2013), chemical investiga-
tion, clinical trials and legal issues may exclude a compound
from further development processes towards a recognized drug.
However, cell culture-based assays cannot provide the full phar-
macological proﬁle since the data they provided are limited to
some molecular and cellular aspects such as pharmacodynamic,
biochemical pathways and genetic variations.
Since cell-culture studies focus on isolated cells apart from
tissues or organisms, the inﬂuence of some elements that can
interfere with the pharmacological receptors for example,
including some chemical environments (Ghanemi et al.,
2013), hormones and ﬂuid pressure cannot be studied. Impor-
tantly, some pharmacokinetic parameters cannot be studied by
cell cultures, and animal experiments remain required to
achieve this purpose. Focusing on the challenges facing the
application of cell culture techniques in drug discovery and
overcoming them would further exploit this important method
for drug discovery and drug development research.Acknowledgment
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